

MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dexamethasone in Transplant-Ineligible Participants With Newly Diagnosed Multiple Myeloma

Estado
Interrumpido

Tipo de Participantes
No aportado

Rangos de Edad
Mayores de 64 , Adultos (18-64 años)

Género
Ambos

Fases
Fase III

Participantes esperados
616

Resultados
Sin resultados

Bajo nivel intervención
No

Enfermedad rara
No

Cobertura geográfica
Sin determinar

Ámbitos del ensayo
tratamiento, seguridad, eficacia,
farmacocinética, farmacodinámica,
farmacoeconómica

Terapia avanzada
NO

Información

Identificador
2024-514139-50-00 (CTIS)

Cod. Protocolo
C1071006

Transicionado 2021-000803-20

Área terapéutica
Enfermedades [C] - Cáncer [C04]

Enfermedad investigada
Multiple myeloma

Título Científico
C1071006 AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE

EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

Justificación

No aportado

Objetivo Principal

Part 1

To assess dose limiting toxicities DLTs of EDR to select an RP3D for the combination to be used in Part 2 of this study.

Part 2

To compare the efficacy of Arm A (EDR) vs Arm B (D-VRd) as measured by MRD status and PFS

Variables de Evaluación Primaria

Part 1: DLTs during the DLT observation period:For all dose levels (DLs) except DL F: From the first priming dose of elranatamab in the 2 Step-up Priming Dose Period until 28 days ($\pm$ visit windows) from the first administration of the EDR combination.

For DL F: 28 days ($\pm$ visit windows) from the day of the first full dose of elranatamab (76 mg) in combination with daratumumab (D) and lenalidomide (R.).

Part 2: MRD negative CR rate (central lab) at 12 months after randomization per IMWG as assessed via next generation sequencing (NGS)

PFS per IMWG

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

Part 1 To evaluate the overall safety profile of EDR or ER to select an RP3D for the combination to be used in Part 2 of this study.

To evaluate the efficacy of EDR or ER to select an RP3D for the combination to be used in Part 2 of this study.

To evaluate the PK of elranatamab when used in the EDR or ER combinations

To evaluate the immunogenicity of elranatamab when used in the EDR or ER combinations (Part 1 only).

To evaluate the PK of daratumumab and lenalidomide when used in EDR or ER combinations

Part 2. To compare the efficacy of Arm A (EDR) vs Arm B (D-VRd) as measured by OS

Variables de Evaluación Secundaria

Part 1: Adverse events (AEs) as characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v5.0), timing, seriousness, and relationship to study treatment. Severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded according to American Society for Transplantation and Cellular Therapy (ASTCT) criteria. Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v5.0), and timing. Objective response rate (ORR) and complete response rate (CRR), per International Myeloma Working Group (IMWG) response criteria as determined by investigator.

Time to event endpoints: time to response (TTR,), duration of response (DOR,), duration of complete response (DOCR) and progression-free survival (PFS) per IMWG response criteria as determined by investigator, and overall survival (OS);

Minimal residual disease (MRD) negative CR rate (central laboratory) per IMWG sequencing criteria.

Predose and post dose concentrations of elranatamab against elranatamab

Anti-drug antibodies (ADAs) and neutralizing antibodies (NABs) against elranatamab

Predose concentrations of daratumumab and lenalidomide

Part 2 Key Secondary: OS

Secondary: Overall MRD negative CR rate per IMWG

Duration of MRD negative CR per IMWG

PFS and progression-free survival on next line of therapy (PFS2) by investigator per IMWG

ORR, CRR, TTR, DOR, and DOCR per IMWG

AEs as characterized by type, frequency, severity (as graded by NCI CTCAE v5.0), timing, seriousness, and relationship to study treatment. The severity of CRS and ICANS will be graded according to ASTCT criteria (Lee, 2019).

Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v5.0), and timing.

Predose and post dose concentrations of elranatamab.

ADAs and NABs against elranatamab.

EORTC QLQ-C30 and MY20European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQC30) and Myeloma Module 20 (MY20).

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

Participants must meet the following inclusion criteria to be eligible for enrollment into the study. Criteria are for both Part 1 and Part 2 unless otherwise specified: Age and Sex: Participant's age 18 years (or the minimum country specific age of consent if >18) at Visit 1 (Screening). Part 2 only: Participant has NDMM and is transplant-ineligible. In Part 2, transplant-ineligible is defined as: Participants not considered candidates for high-dose chemotherapy and ASCT due to age or Participants with important comorbidities likely to have a negative impact on tolerability of high dose chemotherapy and ASCT. Eastern Cooperative Oncology Group (ECOG) performance status 2. Adequate hepatic, renal, and bone marrow (BM) function (absolute neutrophil count [ANC], platelet count, hemoglobin). Corrected serum calcium 14 mg/dL (3.5 mmol/L), or free ionized calcium 6.5 mg/dL (1.6 mmol/L). Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1. Type of Participant and Disease Characteristics: Diagnosis of multiple myeloma (MM) as defined according to IMWG criteria. Measurable disease based on IMWG criteria as defined by at least 1 of the following (as assessed by the central laboratory for Part 2) Serum M-protein 0.5 g/dL (Part 1) and 1g/dL (Part 2) Involved free light chain (FLC) 10 mg/dL (100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65). Part 1 only: Participant with NDMM or RRMM. NDMM participant must be transplant-ineligible. In Part 1 transplant-ineligible is defined by age 65 years or by age <65 years with comorbidities impacting the possibility of transplant. Participants with RRMM must have received 1-2 prior lines of MM therapy including at least one immunomodulatory drug (IMiD) and one proteasome inhibitor (PI).

Criterios de Exclusión

Medical Conditions: Smoldering MM. Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ, or Stage 0/1 with minimal risk of recurrence per investigator. Participants with known or suspected hypersensitivity to the study interventions or any of their excipients. Participants with known or suspected central nervous system (CNS) or clinical signs of myelomatous meningeal involvement. Other surgical (including major surgery within 14 days prior to enrollment), medical or psychiatric conditions including recent (within the past year) or active suicidal ideation/behaviour or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery that may significantly alter the absorption of oral drugs. Gastroesophageal reflux disease under treatment with proton pump inhibitors is allowed (assuming no drug interaction potential). Monoclonal gammopathy of undetermined significance (MGUS). Plasma cell leukemia. Waldenström's Macroglobulinemia. Systemic light chain amyloidosis. Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin abnormalities (POEMS) Syndrome. Impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment. Ongoing Grade 3 (Part 1)/Grade 2 (Part 2) or higher peripheral sensory or motor neuropathy, history of Guillain-Barré syndrome (GBS) or GBS variants, or history of any Grade >3 (Part 1)/Grade >2 (Part 2) peripheral motor polyneuropathy. Active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) coronavirus disease 2019 (COVID-19)/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hepatitis B virus (HBV), hepatitis C virus (HCV), and known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness. Active infections must be resolved at least 21 days prior to enrollment. Participants treated with systemic therapeutic anti-infective agents within 28 days prior to enrollment are not eligible. Prophylactic use of systemic anti-infective agents is permitted.

Calendario

(Última actualización: 04/08/2026)

Autorización 22/12/2022	Inicio de Ensayo 01/03/2023	Inclusión Primer Paciente 17/05/2023	Interrumpido 29/10/2025	Reiniciado No aportado
Fin de reclutamiento No aportado	Fin prematuro (España) No aportado	Fin prematuro (Global) No aportado	Fin del ensayo en España No aportado	Fin del ensayo global No aportado

Promotor

Pfizer Inc. United States

66 Hudson Boulevard East

Contact Person

Clinical Medical Lead

+18007181021

ClinicalTrials.gov_Inquiries@pfizer.com

Monetary support: N/A

Tipo de promotor: Comercial

Ceim

CEIm Hospital Universitari Germans Trias i Pujol

Ctra. Canyet, s/n Edificio General - 1a planta / Módulos urgencias - 1a planta 08916 Badalona

ceic.germanstrias@gencat.cat

934978956

Centros

Activo (09/03/2020)	Clinica Universidad De Navarra Pamplona NAVARRA N/A
Activo (21/11/2025)	Complejo Hospitalario Universitario De Santiago Santiago De Compostela CORUÑA N/A
Activo (03/03/2020)	Hospital Clinic De Barcelona Barcelona BARCELONA N/A
Activo (03/05/2020)	Hospital Germans Trias I Pujol Badalona BARCELONA Instituto Catalán de Oncología de Badalona
Activo (09/02/2024)	Hospital San Pedro De Alcantara Caceres CÁCERES N/A
Activo (21/12/2023)	Hospital Universitari Mutua Terrassa Terrassa BARCELONA N/A
Activo (01/03/2020)	Hospital Universitario De La Princesa Madrid MADRID N/A
Activo (23/03/2020)	Hospital Universitario Dr Peset Aleixandre Valencia VALENCIA N/A

Activo (10/06/2024)	Hospital Universitario Fundacion Jimenez Diaz	
	Madrid	
	MADRID	
	N/A	

Activo (23/06/2026)	Hospital Universitario Marques De Valdecilla	
	Santander	
	CANTABRIA	
	N/A	

Activo (05/06/2026)	Hospital Universitario Regional De Malaga	
	Malaga	
	MÁLAGA	
	N/A	

Activo (15/06/2026)	Hospital Universitario Y Politecnico La Fe	
	Valencia	
	VALENCIA	
	Hematología y Hemoterapia	

Activo (15/11/2023)	Institut Catala Dáncologia	
	L'hospitalet De Llobregat	
	BARCELONA	
	Haematology Department	

No iniciado (-/-/----)	Institut Catala Dáncologia	
	Girona	
	GERONA	
	Hematología Clínica	

Medicamentos

Zelvina 15 mg hard capsules

CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA

Principios Activos: N/A

Experimental

Privigen 100 mg/ml solution for infusion

SOLUTION FOR INFUSION
IV INFUSION

Código ATC: J06BA02 - INMUNOGLOBULINAS HUMANAS
NORMALES PARA ADM. INTRAVASCULAR

Principios Activos: N/A

Experimental

ELRANATAMAB

SOLUTION FOR INJECTION
SUBCUTANEOUS USE

Principios Activos: N/A

Experimental

Zelvina 2.5 mg hard capsules

CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA

Principios Activos: N/A

Experimental

Zelvina 5 mg hard capsules

CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA

Principios Activos: N/A

Experimental

Dexamethasone 0.5mg Tablets

TABLET
ORAL USE

Código ATC: H02AB02 - DEXAMETASONA

Principios Activos: N/A

Experimental

Zelvina 25 mg hard capsules

CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA

Principios Activos: N/A

Experimental

Nodexon 20 mg tabletid

TABLET
ORAL USE

Código ATC: H02AB02 - DEXAMETASONA

Principios Activos: N/A

Experimental

Nodexon 20 mg tablets

TABLET
ORAL USE

Código ATC: H02AB02 - DEXAMETASONA
Principios Activos: N/A

Experimental

Nodexon 20 mg tablets

TABLET
ORAL USE

Código ATC: H02AB02 - DEXAMETASONA
Principios Activos: N/A

Experimental

Nodexon 20 mg tablets

TABLET
ORAL USE

Código ATC: H02AB02 - DEXAMETASONA
Principios Activos: N/A

Experimental

DARZALEX 1800 mg solution for injection

SOLUTION FOR INJECTION
SUBCUTANEOUS USE

Código ATC: L01FC01 - DARATUMUMAB
Principios Activos: N/A

Huérfano

Experimental

Dexamethasone 4 mg tablets

TABLET
ORAL USE

Código ATC: H02AB02 - DEXAMETASONA
Principios Activos: N/A

Experimental

VELCADE 3.5 mg powder for solution for injection

SOLUTION FOR INJECTION
SUBCUTANEOUS

Código ATC: L01XG01 - BORTEZOMIB
Principios Activos: N/A

Experimental

Zelvina 10 mg hard capsules

CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA

Principios Activos: N/A

Experimental

Sin resultados

MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dexamethasone in Transplant-Ineligible Participants With Newly Diagnosed Multiple Myeloma

State

Halted

Type of participants

Not provided

Age Ranges

Older than 64 , Adults (18-64 years)

Gender

Both

Phases

Phase III

Expected Participants

616

Results

No results

Low level of intervention

No

Rare disease

No

Geographic coverage

Undetermined

Areas of the study

treatment, safety, effectiveness,
pharmacokinetics, pharmacodynamics,
pharmacoeconomic

Advanced therapy

NO

Information

Identifier

2024-514139-50-00 (CTIS)

Protocol Code

C1071006

Transitioned 2021-000803-20

Therapeutic area

Diseases [C] - Cancer [C04]

Investigated Disease

Multiple myeloma

Scientific Title

C1071006 AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE

EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

Rationale

Not provided

Main Objective

Part 1

To assess dose limiting toxicities DLTs of EDR to select an RP3D for the combination to be used in Part 2 of this study.

Part 2

To compare the efficacy of Arm A (EDR) vs Arm B (D-VRd) as measured by MRD status and PFS

Primary Endpoints

Part 1: DLTs during the DLT observation period:For all dose levels (DLs) except DL F: From the first priming dose of elranatamab in the 2 Step-up Priming Dose Period until 28 days ($\pm$ visit windows) from the first administration of the EDR combination.

For DL F: 28 days ($\pm$ visit windows) from the day of the first full dose of elranatamab (76 mg) in combination with daratumumab (D) and lenalidomide (R.).

Part 2: MRD negative CR rate (central lab) at 12 months after randomization per IMWG as assessed via next generation sequencing (NGS)

PFS per IMWG

Temporary moments of secondary assessment

Not provided

Secondary Objective

Part 1 To evaluate the overall safety profile of EDR or ER to select an RP3D for the combination to be used in Part 2 of this study.

To evaluate the efficacy of EDR or ER to select an RP3D for the combination to be used in Part 2 of this study.

To evaluate the PK of elranatamab when used in the EDR or ER combinations

To evaluate the immunogenicity of elranatamab when used in the EDR or ER combinations (Part 1 only).

To evaluate the PK of daratumumab and lenalidomide when used in EDR or ER combinations

Part 2. To compare the efficacy of Arm A (EDR) vs Arm B (D-VRd) as measured by OS

Secondary Endpoints

Part 1: Adverse events (AEs) as characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v5.0), timing, seriousness, and relationship to study treatment. Severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded according to American Society for Transplantation and Cellular Therapy (ASTCT) criteria. Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v5.0), and timing. Objective response rate (ORR) and complete response rate (CRR), per International Myeloma Working Group (IMWG) response criteria as determined by investigator.

Time to event endpoints: time to response (TTR,), duration of response (DOR,), duration of complete response (DOCR) and progression-free survival (PFS) per IMWG response criteria as determined by investigator, and overall survival (OS);

Minimal residual disease (MRD) negative CR rate (central laboratory) per IMWG sequencing criteria.

Predose and post dose concentrations of elranatamab against elranatamab

Anti-drug antibodies (ADAs) and neutralizing antibodies (NABs) against elranatamab

Predose concentrations of daratumumab and lenalidomide

Part 2 Key Secondary: OS

Secondary: Overall MRD negative CR rate per IMWG

Duration of MRD negative CR per IMWG

PFS and progression-free survival on next line of therapy (PFS2) by investigator per IMWG

ORR, CRR, TTR, DOR, and DOCR per IMWG

AEs as characterized by type, frequency, severity (as graded by NCI CTCAE v5.0), timing, seriousness, and relationship to study treatment. The severity of CRS and ICANS will be graded according to ASTCT criteria (Lee, 2019).

Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v5.0), and timing.

Predose and post dose concentrations of elranatamab.

ADAs and NABs against elranatamab.

EORTC QLQ-C30 and MY20European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQC30) and Myeloma Module 20 (MY20).

Temporary moments of secondary assessment

Not provided

Inclusion criteria

Participants must meet the following inclusion criteria to be eligible for enrollment into the study. Criteria are for both Part 1 and Part 2 unless otherwise specified: Age and Sex: Participant's age 18 years (or the minimum country specific age of consent if >18) at Visit 1 (Screening). Part 2 only: Participant has NDMM and is transplant-ineligible. In Part 2, transplant-ineligible is defined as: Participants not considered candidates for high-dose chemotherapy and ASCT due to age or Participants with important comorbidities likely to have a negative impact on tolerability of high dose chemotherapy and ASCT. Eastern Cooperative Oncology Group (ECOG) performance status 2. Adequate hepatic, renal, and bone marrow (BM) function (absolute neutrophil count [ANC], platelet count, hemoglobin). Corrected serum calcium 14 mg/dL (3.5 mmol/L), or free ionized calcium 6.5 mg/dL (1.6 mmol/L). Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1. Type of Participant and Disease Characteristics: Diagnosis of multiple myeloma (MM) as defined according to IMWG criteria. Measurable disease based on IMWG criteria as defined by at least 1 of the following (as assessed by the central laboratory for Part 2) Serum M-protein 0.5 g/dL (Part 1) and 1g/dL (Part 2) Involved free light chain (FLC) 10 mg/dL (100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65). Part 1 only: Participant with NDMM or RRMM. NDMM participant must be transplant-ineligible. In Part 1 transplant-ineligible is defined by age 65 years or by age <65 years with comorbidities impacting the possibility of transplant. Participants with RRMM must have received 1-2 prior lines of MM therapy including at least one immunomodulatory drug (IMiD) and one proteasome inhibitor (PI).

Exclusion criteria

Medical Conditions: Smoldering MM. Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ, or Stage 0/1 with minimal risk of recurrence per investigator. Participants with known or suspected hypersensitivity to the study interventions or any of their excipients. Participants with known or suspected central nervous system (CNS) or clinical signs of myelomatous meningeal involvement. Other surgical (including major surgery within 14 days prior to enrollment), medical or psychiatric conditions including recent (within the past year) or active suicidal ideation/behaviour or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery that may significantly alter the absorption of oral drugs. Gastroesophageal reflux disease under treatment with proton pump inhibitors is allowed (assuming no drug interaction potential). Monoclonal gammopathy of undetermined significance (MGUS). Plasma cell leukemia. Waldenström's Macroglobulinemia. Systemic light chain amyloidosis. Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin abnormalities (POEMS) Syndrome. Impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment. Ongoing Grade 3 (Part 1)/Grade 2 (Part 2) or higher peripheral sensory or motor neuropathy, history of Guillain-Barré syndrome (GBS) or GBS variants, or history of any Grade >3 (Part 1)/Grade >2 (Part 2) peripheral motor polyneuropathy. Active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) coronavirus disease 2019 (COVID-19)/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hepatitis B virus (HBV), hepatitis C virus (HCV), and known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness. Active infections must be resolved at least 21 days prior to enrollment. Participants treated with systemic therapeutic anti-infective agents within 28 days prior to enrollment are not eligible. Prophylactic use of systemic anti-infective agents is permitted.

Calendar

(Last Update: 04/08/2026)

Authorization	Start of Trial	First patient inclusion	Halted	Restarted
22/12/2022	01/03/2023	17/05/2023	29/10/2025	Not aported

End of recruitment	Premature end (Spain)	Premature End (Global)	Trial end (Spain)	Trial end (Global)
Not aported	Not aported	Not aported	Not aported	Not aported

Sponsor

Pfizer Inc. United States

66 Hudson Boulevard East

Contact Person

Clinical Medical Lead

+18007181021

ClinicalTrials.gov_Inquiries@pfizer.com

Monetary support: N/A

Sponsor type: Commercial

Ceim

CEIm Hospital Universitari Germans Trias i Pujol

Ctra. Canyet, s/n Edificio General - 1a planta / Módulos urgencias - 1a planta 08916 Badalona

ceic.germanstrias@gencat.cat

934978956

Sites

Active (09/03/2020)	Clinica Universidad De Navarra Pamplona NAVARRA N/A
Active (21/11/2025)	Complejo Hospitalario Universitario De Santiago Santiago De Compostela CORUÑA N/A
Active (03/03/2020)	Hospital Clinic De Barcelona Barcelona BARCELONA N/A
Active (03/05/2020)	Hospital Germans Trias I Pujol Badalona BARCELONA Instituto Catal&aacute;n de Oncolog&iacute;a de Badalona
Active (09/02/2024)	Hospital San Pedro De Alcantara Caceres CÁCERES N/A
Active (21/12/2023)	Hospital Universitari Mutua Terrassa Terrassa BARCELONA N/A
Active (01/03/2020)	Hospital Universitario De La Princesa Madrid MADRID N/A
Active (23/03/2020)	Hospital Universitario Dr Peset Aleixandre Valencia VALENCIA N/A

Active (10/06/2024)	Hospital Universitario Fundacion Jimenez Diaz	
	Madrid	
	MADRID	
	N/A	

Active (23/06/2026)	Hospital Universitario Marques De Valdecilla	
	Santander	
	CANTABRIA	
	N/A	

Active (05/06/2026)	Hospital Universitario Regional De Malaga	
	Malaga	
	MÁLAGA	
	N/A	

Active (15/06/2026)	Hospital Universitario Y Politecnico La Fe	
	Valencia	
	VALENCIA	
	Hematología y Hemoterapia	

Active (15/11/2023)	Institut Catala Dáoncologia	
	L'hospitalet De Llobregat	
	BARCELONA	
	Haematology Department	

not initialized (---/---/----)	Institut Catala Dáoncologia	
	Girona	
	GERONA	
	Hematología Clínica	

Medication

Zelvina 15 mg hard capsules

CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA

Active Principles: N/A

Experimental

Privigen 100 mg/ml solution for infusion

SOLUTION FOR INFUSION
IV INFUSION

ATC code: J06BA02 - INMUNOGLOBULINAS HUMANAS NORMALES PARA ADM. INTRAVASCULAR

Active Principles: N/A

Experimental

ELRANATAMAB

SOLUTION FOR INJECTION
SUBCUTANEOUS USE

–
Active Principles: N/A

Experimental

Zelvina 2.5 mg hard capsules

CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA

Active Principles: N/A

Experimental

Zelvina 5 mg hard capsules

CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA

Active Principles: N/A

Experimental

Dexamethasone 0.5mg Tablets

TABLET
ORAL USE

ATC code: H02AB02 - DEXAMETASONA

Active Principles: N/A

Experimental

Zelvina 25 mg hard capsules

CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA

Active Principles: N/A

Experimental

Nodexon 20 mg tabletid

TABLET
ORAL USE

ATC code: H02AB02 - DEXAMETASONA

Active Principles: N/A

Experimental

Nodexon 20 mg tablets

TABLET

ORAL USE

ATC code: H02AB02 - DEXAMETASONA

Active Principles: N/A

Experimental

Nodexon 20 mg tablets

TABLET

ORAL USE

ATC code: H02AB02 - DEXAMETASONA

Active Principles: N/A

Experimental

Nodexon 20 mg tablets

TABLET

ORAL USE

ATC code: H02AB02 - DEXAMETASONA

Active Principles: N/A

Experimental

DARZALEX 1800 mg solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

ATC code: L01FC01 - DARATUMUMAB

Active Principles: N/A

Orphan

Experimental

Dexamethasone 4 mg tablets

TABLET

ORAL USE

ATC code: H02AB02 - DEXAMETASONA

Active Principles: N/A

Experimental

VELCADE 3.5 mg powder for solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS

ATC code: L01XG01 - BORTEZOMIB

Active Principles: N/A

Experimental

Zelvina 10 mg hard capsules

CAPSULE, HARD

ORAL USE

ATC code: L04AX04 - LENALIDOMIDA

Active Principles: N/A

Experimental

No results